Status:
UNKNOWN
Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia
Lead Sponsor:
Assiut University
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
18-50 years
Phase:
PHASE4
Brief Summary
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. It is a polygenetic condition with variable degree of severit...
Detailed Description
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. It is a polygenetic condition with variable degree of severit...
Eligibility Criteria
Inclusion
- Only males with Androgenetic Alopecia.
- Age (18 - 50) years.
- AGA grade II to VII according to Norwood-Hamilton classification
Exclusion
- Females with Androgentic Alopecia.
- Previous history of sensitivity to Cetirizine.
- Previous treatment for AGA in the last in the last 3 months
- Chronic Systemic diseases as; hypotension, cardiac patients, renal failure or liver failure.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04293822
Start Date
June 1 2020
End Date
November 1 2021
Last Update
March 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt, 71515